



Leading Research into Head and Neck Cancer

**Funding world class research to
discover newer and kinder treatments for
head and neck cancer**

**Annual report and audited accounts
2017 - 2018**

www.oraclecancertrust.org



Oracle Cancer Trust is the UK's leading national charity dedicated to funding research into head and neck cancer

CONTENTS

Chairman's Report.....	4
CEO's Report.....	5
Research.....	6-7
About head and neck cancer.....	8-9
Fundraising	10-11
Oracle's Objectives for 2018-2019	12
Review of Financial Position.....	13
Structure, Governance and Management	14
Legal and Administrative Information	15
Independent Auditor's Report to the Members of Oracle Cancer Trust.....	17
Statement of Financial Activities for the year ending 31 May 2018	20
Balance Sheet.....	21
Statement of Cash Flows	22
Notes to the Financial Statements.....	23

Chairman's Report



Introduction

I am delighted to report that Oracle is going from strength to strength and we have reported a significant increase in donor income to help us fund more projects than ever before to help us discover newer and kinder treatments for this devastating group of cancers.

In late 2017 HRH Princess Alexandra officially retired as Oracle's Patron and I was delighted that acclaimed author, Sir Michael Morpurgo, agreed to take over the role. Michael has had a personal experience of head and neck cancer having been diagnosed with cancer of the larynx, and with his support we can continue to raise awareness about head and neck cancer and our vital research work.

The Oracle Team

Our Head of Fundraising, Emma Colliver has made a tremendous impact to the charity and I would like to thank her for all her enthusiasm and hard work. Emma has now gone to pursue her dream of doing a cancer research PhD at the prestigious Crick Institute in London and on behalf of everyone at the charity we wish her well in her new career.

I am delighted that our Voluntary CEO Jamie Newall has devoted his time and enthusiasm supporting the charity and ensuring that we continue to maintain the highest levels of governance, particularly with our growing portfolio of research projects and research institutions.

The charity is run by a small team of part-time staff who do such a tremendous job running the charity, as well as the dedicated volunteers who support us throughout the year at events. This year we held several events, including our popular golf day, quiz night, our third research evening and our annual Christmas concert, The Glory of Christmas, now in its 12th year. The concert is as popular as ever and we were delighted that actress Clare Holman joined us at this year's event to read a short poem.

Our new association with the Oxford-based Charity Heads Up has been very successful and we were delighted that so many new supporters joined us at a special evening reception held at Oriol College, Oxford in September 2017. The voluntary team at Heads Up share Oracle's vision and values and our relationship has gone from strength to strength.

Finally, I would also like to make a tribute to Sir Adrian Swire who passed away in the Autumn of 2018. As well as being one of Oracle's Vice-President's, Sir Adrian generously funded many of our pioneering research projects and we are truly indebted for his support over the years. Sir Adrian's funding has provided several breakthrough studies, particularly in researching how radiotherapy can be delivered to reduce the often lifelong side-effects including dry mouth, impaired swallowing and taste.



Peter Rhys Evans
Chairman and Founder, Oracle Cancer Trust

CEO's Report



Introduction

My first full year as Oracle's voluntary CEO has been one of growth and change as we continue to face the challenges of a small charity (one permanent member of staff and two on a part-time consultancy basis) delivering within our niche.

Overview

2017-2018 benefited from a full-time Head of Fundraising, Emma Colliver. Allied to the strong governance foundations laid in previous years this has led to an increase in income to £575,160, a 72% growth from the previous reporting period.

In addition, we joined forces with Heads Up, an Oxford based head and neck cancer charity, strengthening our Research Committee with the addition of Mr Stuart Winter MD, MB, ChB, BSc, FCRS and Dr Ketan Shah, D Phil (Oxon) FRCR MRCP PGDip (Oncology) BMBCh (Oxon). We also welcomed Accountant James Robertson to our Finance and Investment Committee and key Heads Up's volunteers Ray Derkacz and Leigh-Anne El-Barhdadi.

By collaborating with a very similar charity we progressed two key parts of our strategy. Firstly, to be a truly national charity, not just one perceived as being London focused, thereby giving us a stronger voice in representing our cause with donors, research institutions and other bodies. Secondly, by bringing together similar charities we can share the necessary overheads, mainly caused by governance requirements, ensuring the maximum possible amount of donations can be spent on research.

Research

In this report there is an overview of some of the projects that Oracle has funded and is overseeing during this period. Oracle's sole remit is to support early stage research projects that help improve outcomes for patients.

Our projects continue to have successful outcomes with improvement to patient treatments, projects moving forward to clinical trials and publications in key medical and scientific journals. Our annual Research Event held in late 2017 at the Grange City Hotel, with over seventy people attending, showcased the exciting developments we have funded whilst giving our donors a chance to meet the researchers and hear presentations from the project leads.

Supporters

All our funding comes from private supporters, individuals, foundations, trusts and corporates. One thing that has become clear to me this year is those who support us in other ways, not just our incredible volunteers but also those individuals and corporates who give their time and expertise pro-bono. They enable Oracle to deliver an incredible amount with such a small core team and I would like to give thanks to them all for their invaluable contribution to our work.

This year I would like to particularly mention City law firm Dorsey's LLP, who provide all our legal advice pro-bono and the Grange Hotel Group, run by long-time supporter Tony Matharu, who generously sponsored the venue and catering for our research event and has pledged his support to continue in the coming years. We are also delighted to have been named the Local Area Building Control (LABC) charity of the year and will benefit from all their fundraising efforts.

Conclusion

Once again, I would like to thank you all for the support you continue to give the charity. This has been a challenging but rewarding period for Oracle Cancer Trust and I anticipate this will continue in 2018-2019.

A handwritten signature in black ink, appearing to read 'Jamie Newall', written in a cursive style.

Jamie Newall
CEO (Voluntary)

Research Summary



2017-2018 has been another accomplished year for Oracle Cancer Trust.

The total cost of research projects ongoing in 2018, including grants already held as well as new ones, came to over £1.5million, with this year's research spend being just over £428,000.

Whilst we continue to tackle new areas of research, past projects continue to provide the groundwork for future research and development of novel treatments.

For example, back in 2015, Prof. Chris Nutting began an investigation into reducing long term swallowing problems through development of novel advanced radiotherapy techniques which now continues to get closer to use in practice. The definitive role of this technique is currently under evaluation in the DARS trial, a CRUK sponsored national phase 3 trial. Results from this study will determine whether it should be used as standard of care in routine practice and help to reduce one of the brutal side effects of radiotherapy in head and neck cancer patients.

As the incidence of head and neck cancer continues to rise, so must our mission to combat the disease with innovative and kinder treatments for patients. In order to do so we are continuing to grow our portfolio of research, including expanding out to new institutions; as well as The Institute of Cancer Research and The Royal Marsden Hospital we are now also funding projects at the University of Oxford and The Blizard Institute (Barts and The London School of Medicine and Dentistry). We want to continue to increase our reach across leading institutions throughout the UK in 2019.

The fascinating work carried out by researchers across these sites was showcased at our 3rd Annual Research Reception in October 2017.

New research projects in 2017-2018


“Taste dysfunction following radiotherapy for head and neck cancer”

Dr Lucinda Gunn, The Royal Marsden Hospital

Taste dysfunction is one of the most frequent complaints of patients undergoing radiotherapy for head and neck cancer and is reported in up to 75% of patients. Some patients lose their sense of taste whilst others report a changing perception of taste. Unfortunately, it plays a major role in patients developing anorexia, weight loss and malnutrition.

Dr Lucinda Gunn’s research will investigate the association between radiotherapy dose and patient-reported taste dysfunction by studying taste in patients undergoing treatment. She hopes to:

- *Understand the prevalence and pattern of taste loss seen in patients*
- *Study those in which taste function remains a persistent problem at 6 months*
- *Understand more about the mechanism of injury to taste*
- *Develop strategies to reduce taste loss*



“Use of 89Zr based immune-PET to study immune checkpoint inhibitor (ICPI) therapy in head and neck cancer”

Julia Hoebart, The Institute of Cancer Research

We know that activating the immune system is a powerful tool in the fight against cancer, but tumours can be very good at hiding from the immune system. Julia is working to establish a marker that will help visualise ‘immune checkpoints’ in the body, which when inhibited using a drug, trigger immune attack on tumours. However, not all patients respond to these novel immunotherapy drugs and therefore establishing an imaging technique to study the mechanisms behind these drugs and how they can be improved will hopefully lead to more effective treatments for patients.



“Imaging biomarkers of resistance in head and neck cancer: Useful tools to inform and guide treatment management”

Dr Florian Raes, The Institute of Cancer Research

Positron emission tomography (PET) allows non-invasive imaging of a range of tumour biomarkers. In a pre-treatment setting, these biomarkers can help clinicians to select the most appropriate initial treatment and provide information on how well that treatment is working.

Pictured right: Julia Hoebart with Dr Florian Raes, image courtesy of The ICR




About head and neck cancer

Head and neck cancer is the cause of 380,000 deaths a year, worldwide^[1]. Incidence varies from country to country for example, head and neck cancer accounts for 7-8% of all cancers in the UK whereas in Asia the burden is even more significant with around 30-40% of cancers occurring in the head and neck.

As well as impacting individuals and their families, head and neck cancer also has a negative impact on a country's economy. In 2010, across India, Pakistan and Bangladesh, economic welfare losses due to head and neck cancer was estimated at US\$16.9 billion (2010 USD, PPP), equivalent to 0.26% of their combined gross domestic product (GDP)^[2].

Although it is the sixth most common type of cancer, head and neck cancer falls behind others such as breast, lung and prostate in both awareness and research funding. In fact, a report released by The Institute of Cancer Research in late 2018 that analysed access to innovative cancer drugs also found that whilst 19 new drugs were authorised for lung cancer by the European Medicines Association between 2009-2016, none were authorised for head and neck cancer. Despite needing more attention in comparison to other cancers, ongoing research in head and neck cancer has brought about lifechanging advancements in treatments for patients. Oracle Cancer Trust is the UK's leading national charity at the forefront of funding vital early stage research in the UK into head and neck cancer.



Cancer can develop in more than 30 areas within the head and neck, including the lips and mouth, throat (pharynx), voice box (larynx), salivary glands, nose and sinuses and back of the nose and mouth (nasopharynx). Established risk factors of head and neck cancer include tobacco, alcohol and the Human Papilloma Virus (HPV). Whilst more commonly known as a cause of cervical cancer, HPV associated head and neck cancer is on the rise, in particular HPV-positive tonsillar cancer in younger patients. As with most diseases, early detection can greatly improve outcome for patients therefore awareness is key in the fight against head and neck cancer but with symptoms differing across the many types, it can also be difficult to spot.

Often, following treatment, head and neck cancer becomes a very visible disease. Standard treatments including chemotherapy, radiotherapy and surgery on such a complex area of the body can really leave their mark on patients.

Life changing affects include difficulty with breathing, swallowing, speech, damage to senses including loss of taste and smell, and also change in physical appearance as a result of surgery. It can have a huge impact on quality of life. One study showed that among patients with head and neck cancer, 39% percent had depressive symptoms and 43% high levels of anxiety^[3].

Devastatingly, for survivors of head and neck cancer there is an increased risk of suicide compared with other cancers^[4]. Therefore, not only is there a need to improve outcomes in terms of being able to cure more patients but also to find kinder treatments that give survivors a better chance of getting back to life as they knew it before cancer.

Research into new ways of improving treatment for head and neck cancers has gone a long way into tackling some of these issues for example, breakthroughs in immunotherapy, treatments which trigger the bodies own immune system to kill cancer cells, avoiding damage to healthy tissue caused by chemotherapy and radiotherapy. Currently licensed for patients with advanced head and neck cancer, the immunotherapy pembrolizumab was shown to increase survival in some patients by as much as three years^[5].

Chief Executive of The Institute of Cancer Research, London, Professor Paul Workman said:

“Immunotherapies are already revolutionising treatment for several cancer types, and I am excited to see the new drug pembrolizumab now showing benefit in advanced head and neck cancer. The next big challenge is to design immunotherapies that can work for many more people, so that more patients can benefit from the kinds of dramatic responses that we saw in some patients in this trial.”

We have also seen advancements in surgical techniques including the development of robotic surgery to perform minimally invasive and precise produces inside the mouth. Transoral robotic surgery enables surgeons to access tumours that would normally be difficult, if not impossible to reach. The use of this robot avoids large incisions to the neck and jaw, making it less traumatic for patients and decreasing recovery times.



Robotic surgery is enabling surgeons to access tumours that would normally be difficult to reach

A project currently funded by Oracle Cancer Trust is using this new technique to remove hard to reach tissue from the base of the tongue for testing to help increase detection of tumours in head and neck cancer.

Radiotherapy is also becoming more refined; in 2004, Oracle Cancer Trust funded a clinical research fellow to work under the supervision of Prof. Chris Nutting, to design a treatment protocol to test the effect of reducing the dose of radiotherapy delivered to the salivary glands during head and neck cancer treatment. The technique used is known as intensity-modulated radiotherapy (IMRT). It was hoped that by doing this, fewer patients would develop the side-effect of permanent dry mouth caused by damage to the salivary glands. This work laid the foundations for a UK-wide clinical trial. The results were stunning. By adapting treatment, after 24 months only 29% of patients reported they were suffering with dry mouth following treatment compared to 83% who received conventional radiotherapy⁽⁶⁾. That means dry mouth was avoided in over half of patients undergoing treatment.



Advances in radiotherapy to the head and neck have resulted in up to an 83% reduction of patients suffering from dry mouth following treatment

Prof. Nutting and his team of researchers have also studied the use of IMRT to reduce damage to swallowing, currently being evaluated in the follow up stage of a phase III clinical trial. As well as dry mouth and swallowing difficulties, change or loss of taste is another common complaint of patients following radiotherapy. Prof. Nutting is overseeing a 2-year research project that began in 2018, funded by Oracle Cancer Trust, to determine how damage to taste is caused and importantly for patients, how it can be reduced.

Another exciting advancement in the field of radiotherapy, a technology known as Magnetic Resonance Linear Accelerator (MR Linac) was used to treat a patient with prostate cancer for the first time ever in the UK at The Royal Marsden Hospital in late 2018. This treatment allows more accurate delivery of radiotherapy by tracking tumours in real time, accounting for changes over the course of treatment. This helps target radiotherapy to the tumour and avoid damage to healthy tissue. Researchers funded by Oracle Cancer Trust are now looking into how MR Linac could be used to treat head and neck cancer to help physicians plan and deliver radiotherapy.

They aim to design a protocol that will allow adaptation of the radiation beam to the state of tumour immediately before or during the radiation treatment. Not only will this help avoid some of the nasty side effects caused by damage to healthy tissue in the head and neck, but it could also mean reduction in treatment times.



The revolutionary new MR-Linac machine being installed at The Royal Marsden Hospital in Sutton

Mr Peter Rhys-Evans, Consultant ENT (Ear, Nose, Throat) surgeon and founder and chairman of Oracle Cancer Trust said:

'It is clear that momentum is building and I am confident we will continue to make great strides in our treatment of patients and ultimately minimise the impact of head and neck cancer on quality of life.'

References:

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncol* 2017; 3:524.
2. [https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(15\)60851-0.pdf](https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)60851-0.pdf)
3. https://www.macmillan.org.uk/_images/Head-Neck-Cancer_tcm9-282784.pdf
4. <https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.31675>
5. <https://www.icr.ac.uk/news-archive/immunotherapy-keeps-some-patients-with-advanced-head-and-neck-cancer-alive-for-more-than-three-years>
6. <https://www.ncbi.nlm.nih.gov/pubmed/21236730>

Fundraising

Background

At Oracle Cancer Trust, our approach to fundraising has largely been relationship led, as the community of people who know what it is like to face head and neck cancer are our most generous supporters. However, having brought in a dedicated Head of Fundraising to join our small team, the charity is starting to be awarded funding from a wider range of sources, including trusts and foundations. Oracle Cancer Trust does not engage with professional fundraising organisations or partake in house-to-house or street collections.

Fundraising standards

Oracle Cancer Trust is a voluntary member of the Fundraising Regulator and complies with the Charities Act in regard to fundraising. Oracle takes the privacy of its donors very seriously. All personal data is managed in accordance with our published privacy policy which is available on the charity's website. Oracle has not received any complaints associated with fundraising in this or any previous financial year. The small team are extremely proud to take their duties very seriously in the management and safeguarding of donor information.

GDPR Compliance and Supporter Data

In May 2018 Oracle Cancer Trust completed its GDPR compliance programme in readiness for the new EU-wide legislation. With the assistance of volunteer and project management specialist, Ray Derkacz, the team were able to successfully be GDPR ready by the deadline with a retained independent data manager, ClearComm (a division of Kingston Smith), acting as advisors. Responsible use of supporter data is at the very heart of the charity's small operation.

Fundraising report

In 2017-18, Oracle enjoyed a successful year of fundraising and raised £575,160 which was 72% more than the previous 2016-17 year.

This came on the back of the head of fundraising Emma Colliver and the Oracle team working to deliver the first full year of an ambitious fundraising strategy. Key aims were to improve the support offered by the charity to those generously choosing to raise and donate funds, in order to increase the level of donations from donors both old and new. Our aim remains to ensure we offer an excellent, personalised experience of supporting the charity to anyone who chooses to support us. The most important things we have are the relationships we have with our supporters.

Supporters' Initiatives

A large proportion of Oracle's supporters are traditionally people with personal experience of head and neck cancer, along with their family and friends.

These survivors of cancer are often very motivated to provide support to medical research into the cancer type that affected them, to hopefully save others from experiencing what they have. This support is invaluable to Oracle and has helped us to grow to where it is today.

Over 2017-18, Oracle supporters and friends raised over £101,178 through events of all kinds, be it participating in challenge events and through hosting one-off fundraising events.

The charity has annual ballot places at popular challenge events such as Prudential Ride100, The Royal Parks Half-Marathon and in 2018-19 we are also putting together a team for the Vitality 10K. These sporting challenges prove popular with supporters wishing to raise funds for the charity and in 2017-18 more supporters than ever went the extra mile for us.

One stellar example is Julian Gilbert, who having recently recovered from throat cancer chose Oracle to benefit from a year-long series of fundraising events naming it "Julian's Journey." Julian raised over £50,000, an extraordinary amount and his generosity was put towards the work of PhD researcher, Alexandra Rose who is focusing on the very rare cancer, Adenoid Cystic Carcinoma.



Supporter Julian Gilbert established a year-long fundraising campaign following treatment for throat cancer

Oracle Friends

In the charity's 2015-16 Annual Report, Oracle outlined its intention to aim to increase the number of regular donors to Oracle to provide a sustainable source of fundraising for the charity.

In 2016-17, Oracle created the Oracle Friends initiative to celebrate the valuable donation that regular givers make to the charity's work and to encourage new regular donors. It's a way for people to give in a bite-sized way that adds up and gives us some security in planning for the future. While we still have relatively small numbers of Oracle Friends, since it was formally launched in December 2017, we have had 14 new people join us. If we had 800 Oracle Friends, it would cover the cost of a new PhD grant, so our aim is to promote it further in 2018-19.

Major Donors

Oracle continues to be grateful for the support major donors who provide substantial gifts to the charity's work. We class a donation of over £1,000 as a major gift and in 2017-18, they totalled in excess of £116,500. As a small charity, Oracle offers unrivalled personal support and access to our research work with private laboratory tours, giving an opportunity to see the impact of these donations first hand.

Fundraising and events

Corporate Partnerships

Oracle is also ambitious to build relationships with corporate funders and looking to build more partnerships such as traditional Charity of the Year schemes and beneficiary events.

In 2017, Oracle was selected as Charity of the Year by LABC for the nationwide series of awards evenings running from the Spring of 2017 and throughout 2018 and is set to raise in excess of £60,000.

Oracle was also chosen as beneficiary charity for the annual WealthBriefing Awards for the second year running.

Asian Business Publications also chose Oracle Cancer Trust as the beneficiary charity for its prestigious Asian Achievers Awards night in September 2018.

Trusts & Foundations

Oracle is also looking to increase the level of grant funding donated by Trusts & Foundations through both small and large gifts.

The first stage of this process has involved identifying a number of potential funders of medical research and preparing tailored applications to these organisations. We are grateful that more than a dozen Trusts and Foundations made significant contributions to the work of the charity.

As the 2018 annual report goes to print we are pleased to announce that Oracle has been granted membership to the prestigious Association of Medical Research Charities (AMRC), a membership body that represents over 140 medical and health research charities in the UK.

Events

Oracle manages all its events and marketing capabilities in-house and does not utilise external agencies to deliver projects unless on a pro-bono basis. All copywriting and design are also carried out in-house to minimise outgoings for the charity.

Oracle-Led Initiatives

Oracle organises several events throughout the year, both to support fundraising and ensure our community of supporters is aware of the range of research being undertaken to improve diagnosis and treatment of head and neck cancer.

Annual Golf Day, Walton-on-Thames, Surrey

Our eighth annual golf day once again enjoyed beautiful conditions at Burhill Golf Club and this popular annual event was once again enjoyed by the 18 teams. Following golf was entertainment with a silent and live auction.

Annual Research Evening, London

Our third annual event was held in October and was again generously sponsored by Grange Hotels. Over 60 supporters attended this free evening event where the teams of funded researchers and research leads presented research project updates. This event is attracting a growing number of supporters and will remain a staple of our calendar in 2018-19 and beyond.

Heads Up Supporter Evening, Oxford

One such engagement event was arranged by Oracle in September 2017 to welcome the team of trustees, supporters and volunteers from Heads Up. It was a very special evening event held at Oriel College, Oxford. Heads Up joined forces with Oracle in late 2017 with the voluntary team largely based at the Blenheim Head and Neck Centre at The Churchill Hospital Oxford. It was the perfect way to celebrate us joining together.



ENT Surgeon and Heads Up Trustee Stuart Winter addresses guests at Oriel College, Oxford

12th Glory of Christmas Concert, London

The charity's annual celebration of Christmas is a firm favourite in the calendar for all supporters and welcomes over 500 guests every year. The concert features music from The Thames Chamber Orchestra accompanied by the Choir of Christ's College, Cambridge as well as readings by patients and guests. In 2017 we welcomed actress Clare Holman who read a poem at the concert and also welcomed our incoming Patron, Sir Michael Morpurgo as a guest for the evening.



Volunteers at the 2017 WealthBriefing Awards helping with the fundraising at London's Guildhall

Quiz Night, London

The charity organised a quiz event at Fulham Football Club, in partnership with The Fulham Football Club Foundation. The evening was once again a great success and the charity will look to organise another event in 2019.

Communicating with supporters

Oracle updates supporters with general and Oracle research news, donor stories and events information via the website oraclecancertrust.org as well as a newsletter which is sent digitally or via post to supporters. Oracle's website also serves as a resource for research applicants applying to the charity for funding.

Oracle does not engage in cold-calling and follows an "Opt-in" communications policy. Social media is also widely used by the charity and enjoys a growing audience.

Oracle's Objectives for 2018-2019



Professor Vinidh Paleri of The Royal Marsden Hospital in London, leading a robotic surgery project



Dr Adrian Biddle of Queen Mary's University researching a test to predict metastasis in head and neck cancer



Oracle's new Patron, Sir Michael Morpurgo

Oracle currently funds 12 research projects at The Institute for Cancer Research (ICR), one at The Royal Marsden Hospital NHS Foundation Trust, one at The Blizard Institute and one at The University of Oxford.

Our key objective for 2018-19 is to reinforce the position of Oracle Cancer Trust as the leading national head and neck cancer research charity. We will continue having discussions with other, smaller head and neck cancer charities following our successful joining forces with Heads Up, an Oxford based head and neck charity. Key members of Heads Up have joined and strengthened our Research and Finance and Investment Committees and we are benefiting from the experience and passion of their volunteers.

To reinforce this national position Oracle will continue actively seeking research projects from outside the ICR while also continuing to provide leadership in the sector. To support this initiative we will be improving our application process, including advice support for applicants whose applications have genuine merit but fail to meet our application procedures. The research goals of Oracle are available to all applicants and donors thanks to the publication of Oracle's Research Strategy, available on our website.

Early 2019 we were delighted to be accepted as members of the Association of Medical Research Charities (AMRC). Membership will allow Oracle to apply to a number of larger trusts and foundations. This will help to continue our challenge of matching the regular commitments of funding research with irregular donations which continues to be a challenge. We also hope to close our first successful Intellectual Property negotiation, bringing in a new stream of funding for the charity, albeit in this instance a small situation.

We will also be continuing to improve our regular events which include The Glory of Christmas concert, and Research Event which, having outgrown the capacity at The ICR, will continue to be held in the Grange City Hotel in London. The Research Event is growing in numbers every year and it is our objective to make this event not just an opportunity for donors to see where their funds have gone but also as a leading event for the whole head and neck cancer community.

We are fortunate to have such an excellent and dedicated, but very small, team at Oracle Cancer Trust. We hope during 2018-2019 to enhance it with the recruitment of a Research and Medical Communications Officer. The team is backed by volunteers and organisations who provide us with pro-bono support which allows us to keep overheads to a minimum and maximising the percentage of donations that go to research. However, a small charity is required to have the same governance as a large one and this has a cost.

The excellent progress we made in 2017-2018 has meant that our objectives may seem less ambitious for this year. But building on these foundations to become a truly national charity growing our funding and number of projects funded while maintaining the excellent standards we have achieved is no less challenging.

We are now the leading charity solely focused on head and neck cancer research in the UK but this is not an end in itself but rather a platform for us to continue to fund the very best early stage research that has the most chance of improving outcomes for patients.

Review of Financial Position

The year to 31st May 2018 finished with total funds of £885,877 (2017: £939,340).

The total income was £575,160 (2017: £334,077) and total expenditure was £619,321 (2017 : £554,342) including expenditure on research grants of £424,608 (2017 : £371,204).

Going Concern

The Trustees have reviewed the Charity's financial position, taking into account the levels of reserves, cash, investments and committed income which has not been included in the accounts, future plans and its systems of financial and risk management.

The Trustees believe that the Charity is well placed to manage operational and financial risks successfully. Accordingly, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operation for the foreseeable future and therefore adopt the going concern basis of accounting in preparing the annual accounts.

Reserves Policy

The reserves policy is intended to be conservative and provide adequate assurance to the Board that Oracle operates as a going concern at all times. This involves reviewing cashflow projections for the ability to fund existing research commitments for a period well beyond the end of the next financial period under both the 'base case' business plan and a more pessimistic 'downside' sensitivity with some appropriate mitigating actions. The projections are prepared for the Oracle Finance and Investment sub-committee to consider when assessing all requests to approve new research funding.

To this end, Oracle Cancer Trust aims to maintain both unrestricted reserves and also cash, including term bank deposits, in excess of the grant accruals committed within creditors under one year. At year end, the level of unrestricted reserve funds was £602,920 and cash was £1,316,772. These were both sufficient to meet the Charity's reserves target policy covering grant accruals committed within creditors under one year of £337,219.


Risk Management

The Trustees review, on a regular basis, the key business risks to the Charity and systems to manage and mitigate exposures, including strategic, financial, operational and reputational risks.

Investment Policy

The Trustees maintain an investment policy to achieve risk adjusted returns appropriate for the Charity in light of its business plan, known commitments and the near term operational liquidity requirements.

The Board resolved to close the loan-based endowment fund, liquidate the investment and accelerate repayment of the outstanding loans during the year. The strategy (as outlined in the 2015/16 annual report) had been to grow these loans from supporters to £650,000 by May 2019. However there had been no new subscriptions from the initial four loans of £25,001 each on 23 September 2015 and thus it was no longer considered realistic for Oracle to achieve the pool of capital so as to yield a significant and predictable income stream from this funding source. The final investment proceeds realised were sufficient to meet the outstanding loan liabilities and the surplus along with the investment income received in the intervening period was deemed to have approximately covered the professional fees and governance costs borne by Oracle. (More information may be found within the notes to the accounts: Fixed Asset Investment; and Creditors - due after 1 year).



Dr Furrat Amen presents results of his Oracle funded research at the prestigious ASCO Conference in Chicago, USA



Prof. Kevin Harrington at the Hong Kong International Oncology Forum



Structure, Governance and Management

i. Objects and Activities

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard for the Charity Commission's general guidance on public benefit including its guidance "Public Benefit : Running a Charity (PB2)". The objectives of Oracle Cancer Trust as set out in its Articles of Association are research into all matters connected with or bearing upon the causes, prevention, treatment and care of cancer to include research into, and to advance the art and science of, surgery as applied to cancer of the head, neck and thyroid and for the publication and dissemination of the results of such researches.

ii. Corporate Structure

Oracle Cancer Trust was incorporated as a company limited by guarantee on 14th January 2010 and is governed by its Memorandum and Articles of Association. It was registered by the Charity Commission on 20th May 2011 to continue the activities previously carried out by the unincorporated charity called the Head and Neck Cancer Research Trust (HNCRT), which had been established in 1979. The assets of the HNCRT were transferred to the Trust on 1st June 2011.

iii. The Board of Trustees

The Trustees of Oracle Cancer Trust (who are also Directors for purposes of Company Law) are listed on page 15. The Board is chaired by Peter Rhys Evans who is an eminent head and neck cancer surgeon. Honorary Trustees are leaders in the field of cancer surgery and medicine and include Professor Kevin Harrington, Professor Chris Nutting, Dr Kate Newbold, Dr Ketan Shah and Mr Stuart Winter. Board Directors and Trustees are leading industry figures and have varied backgrounds including finance, media, learning, retail and banking. Oracle's Trustees are sufficiently knowledgeable and experienced in their respective fields to provide the required governance and oversight of the Trust's activities. New Trustees (both full and Honorary) are selected by a two stage process. Initially the Nominations Committee examines a wide array of possible candidates that are reviewed by The Board. The Board then selects the candidate/s to formally approach by majority decision. All Trustees, key management personnel and independent members of committees are required to sign a Conflicts of Interest Policy.

iv. Management

Voluntary CEO and Trustee Jamie Newall continues in his role overseeing the key decisions running the charity and is actively involved with the Board, Finance and Research Committees. Head of Fundraising Emma Colliver continued in her role generating income for the charity until resigning in June 2018 and being replaced in September 2018 by a part-time freelance Head of Fundraising, Teresa Forgione. Sarah Bender continues to manage the day to day running of the Charity as Head of Marketing and Operations on a freelance, self-employed basis and is joined by Linda Wimble who also works on a self-employed, part-time basis.

v. Finance and Investments Committee

The Finance and Investments Committee, which is chaired by an independent qualified accountant, is responsible for scrutinising and approving all significant expenditures and commitments of the Trust, principally its research funding commitments, prior to ratification by the Board. The Committee also reviews and updates the business plan, cashflow forecasts, investment and risk strategies for board review and approval. Other members include a leading City financier and finance expert.

vi. Research Committee

The Research Committee, to ensure good governance, is chaired by a non-medical Trustee. It is responsible for considering and approving all new applications for research funding, as well as monitoring the performance of existing research funding commitments. Other members are medical experts in non-conflicting roles. The Charity has developed a robust peer-review process and committee and in January 2019 was delighted to have been awarded membership to AMRC (Association of Medical Research Charities) which represents over 140 health and medical research charities.

vii. Office and Administration

In December 2018 the charity relocated to offices in South-West London due to the redevelopment of the existing office space. The new location offers an extremely cost-effective and convenient location for the small team.

The day-to-day administration of Oracle Cancer Trust, which is headed by Sarah Bender on a permanent, part-time, freelance basis, with one part-time assistant, is conducted from Oracle's offices at 10 Parsons Green House, 27 Parsons Green Lane, London SW6 4HH.

Oracle has one full-time employee, Emma Colliver who was appointed in June 2016 as Head of Fundraising and resigned in June 2018 to pursue a PhD in cancer research at The Crick Institute in London. The new Head of Fundraising, Teresa Forgione, works on a part-time basis as a self-employed contractor and joined the charity in July 2018.

Legal and Administrative Information

Charity Name	Oracle Cancer Trust
Trustees	Mr Peter Rhys Evans, MB, BS, LRCP, FRCS, DCC Sir Michael Lockett, KCVO Mr John Fallon Mr Keith Jones Mr James Newall - <i>CEO (Voluntary)</i> Mrs Nicola Ridges-Jones
Honorary Trustees	Prof. Kevin Harrington, BSc MBBS MRCP FRCR FRCP PhD DIC Prof. Christopher Nutting, BSc MBBS MD PhD FRCP FRCR MedFIPEM Dr Kate Newbold, MBChB MRCP FRCPE FRCR MD Dr Ketan Shah, BM, BCh, MA (Cantab), BMChB (Oxon), MRCP(UK) Mr Stuart Winter, BSc, MB ChB, MD, FRCS
Patron	Sir Michael Morpurgo
President	Jimmy Mulville
Vice-Presidents	Nigella Lawson Tony Matharu Jenny Pitman OBE James Filmer-Wilson Sir Adrian Swire (deceased October 2018)
Charity Number	1142037
Company Number	07125497
Principal and Registered Office of Charity	10 Parsons Green House 27 Parsons Green Lane London SW6 4HH
Auditors	Kingston Smith LLP Devonshire House 60 Goswell Road London EC1M 7AD
Bankers	CAF Bank Limited 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 1BE
Solicitors	Dorsey & Whitney LLP 199 Bishopsgate London EC2M 3UT

Statement of Trustees' Responsibilities

The Trustees (who are also Directors of Oracle Cancer Trust for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the Financial Statements comply with the Companies Act 2006.

They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- there is no relevant audit information of which the Charitable's Auditor company is unaware, and;
- the Trustees have taken all relevant steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

Auditors:

Kingston Smith LLP were appointed as the Charity's auditors in the year of review and have indicated their willingness to continue in office.

Small Company Regulations:

These accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Signed on behalf of the Board of Trustees:



Date: 12th February 2019

Mr P H Rhys Evans
Chairman & Trustee

Independent Auditor's Report to the Members of Oracle Cancer Trust

Opinion

We have audited the financial statements of Oracle Cancer Trust ('the company') for the year ended 31 May 2018 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard Applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 May 2018 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Independent Auditor's Report to the Members of Oracle Cancer Trust

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a Strategic Report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 16, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

Independent Auditor's Report to the Members of Oracle Cancer Trust

- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Date: 14th February 2019

James Saunders FCCA DChA (Senior Statutory Auditor)
for and on behalf of Kingston Smith LLP, Statutory Auditor

Devonshire House
60 Goswell Road
London
EC1M 7AD

Statement of Financial Activities for the year ending 31 May 2018 (Incorporating the Income and Expenditure Account)

	Notes	Restricted Funds 2018	Unrestricted Funds 2018	Total Funds 2018	Total Funds 2017
Income from:		£	£	£	£
Donations and legacies	1	219,470	237,620	457,090	242,450
Fundraising events		-	101,178	101,178	65,823
Investment income	2	2,762	14,130	16,892	25,804
Total income		222,232	352,928	575,160	334,077
Expenditure on:					
Raising voluntary and fundraising income	3	-	157,048	157,048	147,315
Charitable activities	4	172,738	289,535	462,273	407,027
Total Expenditure		172,738	446,583	619,321	554,342
Net gains/(losses) on investments	10	(2,180)	(7,122)	(9,302)	34,505
Net income/(expenditure)		47,314	(100,777)	(53,463)	(185,760)
Reconciliation of Funds					
Total funds brought forward 1 June 2017		210,775	728,565	939,340	1,125,100
Transfer between funds		24,868	(24,868)	-	-
Total funds carried forward at 31 May 2018		£282,957	£602,920	£885,877	£939,340

The notes on pages 23 to 34 form part of these financial statements.


Balance Sheet at 31st May 2018

	Notes	2018		2017	
		£	£	£	£
Fixed Assets					
Tangible	9	492		885	
Investments	10	-		362,053	
			492		362,938
Current Assets					
Debtors	11	59,563		22,993	
Cash at bank and in hand		1,316,772		1,080,858	
		1,376,335		1,103,851	
Creditors: Amounts falling due within one year	12	457,383		434,360	
Net Current Assets			918,952		669,491
Total Assets less Current Liabilities			£919,444		£1,032,429
Creditors: Amounts falling due after one year	13		33,567		93,089
Net Assets			£885,877		£939,340
Funds					
Restricted funds	14		282,957		210,775
Unrestricted funds	15		602,920		728,565
Total funds			885,877		£939,340

The Directors state:

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts. The accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements were approved by the Trustees on the **12th February 2019** and are signed on their behalf by:



Mr P H Rhys Evans
Chairman and Trustee

Company registration No: 07125497

The notes on pages 23 to 34 form part of these financial statements

Statement of Cash Flows for the year ending 31 May 2018

	2018	2018	2017	2017
	£	£	£	£
Net cash used in operating activities (see note below)		(133,729)		(153,974)
Cash flows from investing activities				
Investment income	16,892		25,804	
Proceeds from investment disposals	352,751		-	
Payments to acquire tangible fixed assets	-		(1,180)	
Net cash providing by investing activities		369,643		24,624
Net change in cash and cash equivalents		235,914		(129,350)
Cash and cash equivalents at the beginning of the year		1,080,858		1,210,208
Cash and cash equivalents at the end of the year		1,316,772		1,080,858

Note - reconciliation of net expenditure to net cash flow from operating activities

Net expenditure (as per statement of financial activities)	(53,463)	(185,760)
Investment income	(16,892)	(25,804)
Depreciation of tangible assets	393	295
(Increase)/decrease in debtors	(36,570)	13,496
(Decrease)/increase in creditors	(36,499)	78,304
Net loss/(gain) on investments	9,302	(34,505)
Net cash used in operating activities	(133,729)	(153,974)
Analysis of cash and cash equivalents		
Cash in hand	1,316,772	1,080,858
Total cash and cash equivalents	1,316,772	1,080,858

Notes to the Financial Statements

Accounting Policies

a) Accounting policies

These financial statements are prepared on a going concern basis, under the historical cost convention modified for investments which are accounted for at market value. The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) including Update Bulletin 1. The Company is a public benefit entity for the purposes of FRS 102 and a registered charity established as a company limited by guarantee and therefore has also prepared its financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Companies Act 2006.

Oracle Cancer Trust meets the definition of a public benefit entity under FRS 102.

The financial statements have been prepared in sterling, which is the functional currency of the entity. Monetary amounts in these financial statements are rounded to the nearest pound.

b) Going concern

The trustees have assessed whether the use of the going concern basis is appropriate and have considered possible events or conditions that might cast significant doubt on the ability of the charity to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of approval of the financial statements. In particular the trustees have considered the charitable company's forecasts and projections and have taken account of pressures on donation and investment income. After making enquiries the trustees have concluded that there is a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. The charitable company therefore continues to adopt the going concern basis in preparing its financial statements. At the date of sign off, the trustees confirm there are no material uncertainties in relation to the going concern assumption.

c) Incoming resources

All incoming resources are included in the Statement of Financial Activities when the charity is entitled to the income, the receipt is probable and the amount can be measured reliably. The following specific policies are applied to particular categories of income:

- Legacies are recognised following probate and once there is sufficient evidence that receipt is probable and the amount of the legacy receivable can be measured reliably. Where entitlement to a legacy exists but there is uncertainty as to its receipt or the amount receivable, details are disclosed as a contingent asset until the criteria for income recognition are met.
- Bank interest is accounted for on an accruals basis.
- Voluntary income by way of donations and gifts is included in full in the Statement of Financial Activities when receivable.

d) Resources expended and irrecoverable VAT

Resources expended including grants are included in the Statement of Financial Activities on an accruals basis. Commitment to fund future grants are recognised as liabilities once the obligation has been communicated to the grant recipient. Where there is an annual review or other performance review related conditions which means that the charity may withdraw a commitment if the conditions are not met, the liability is not recognised until the conditions have been fulfilled, and the commitment can no longer be revoked.

Expenditure includes VAT which is not recoverable by the charity.

The majority of costs are attributable to specific charitable activities.

Support costs include central functions and are allocated to cost categories on the basis of staff time spent on those cost categories.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity.

e) Allocation of support costs

Support costs are those functions that assist the work of the Charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel, payroll and governance costs which support the Trusts artistic programmes and activities. These costs have been allocated between cost of raising funds and expenditure of charitable activities on the basis of staff time spent on these cost categories. Further detail can be found in Note 5.

f) Operating leases

The charity classifies the leasing of office equipment as operating leases, the title remains with the lessor. Rental charges are charged on a straight line basis over the lease period.

Notes to the Financial Statements (continued)

Accounting Policies (continued)

g) Tax status

Oracle Cancer Trust has suffered no tax charge, as it is not subject to UK Corporation tax on its charitable activities.

h) Fund Accounting

Funds held by the Charity are either:

Unrestricted general funds - these are funds that can be used in accordance with the charitable objectives at the discretion of the Trustees.

Designated funds - these are funds that are set aside by the Trustees out of unrestricted general funds for specific future purposes or projects.

Restricted funds - these are funds that are subject to restrictions on their expenditure imposed by the donor.

i) Loan funds

Loan funds relates to amounts loaned to the charity on a fixed term of five years with the intention of generating an income of 4% per annum. The loan terms allow the Charity to receive all regular distributions made during the term of the Loan, and any capital uplift in excess of the value of the Loan at term, which it shall use to advance its charitable objects. Should the regular distributions made from the Fund be less than 4% per annum of the value of the Loan then the Charity may, without the prior written consent of the Lender, withdraw from the Fund by selling units on the 30 September so as to achieve a distribution of 4% per annum for the year ending on 30 September (or adjusted down pro-rata if the loan commenced during the year to 30 September). The Charity at its sole discretion shall determine whether it chooses to liquidate units to achieve the 4% per annum distribution. If the Fund ceased regular distributions then it is anticipated that units would be sold to generate the 4% per annum distributions in any year to 30 September.

These loans are considered to meet the conditions for exemption from the requirement to account for these under FRS 102 at amortised cost, as they meet the definition of public benefit entity concessionary loans; as such they are accounted for at their transaction value.

j) Fixed Assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. Computer equipment - straight line over 3 years.

k) Fixed Asset Investments

Investments are initially recognised at their transaction value and subsequently measured at their market value as at the balance sheet date using the closing market price. The Statement of Financial Activities includes the net gains and losses arising on revaluation and disposals throughout the year.

l) Investment income

Investment income is recognised on notification of distribution. Currently, this is when notified by the fund manager.

m) Financial Instruments

Cash and cash equivalents

Cash and cash equivalents include cash at banks and in hand and short term deposits with a maturity date of three months or less.

Debtors and creditors

Debtors and creditors receivable or payable within one year of the reporting date are carried at their at transaction price and subsequently at settlement value. Debtors and creditors that are receivable or payable in more than one year and not subject to a market rate of interest are measured at the present value of the expected future receipts or payment discounted at a market rate of interest with the exception of public benefit entity concessionary loans which are accounted for as set out in (i) above.

Notes to the Financial Statements (continued)

1) Donations and Legacies

		2018	2017
		£	£
Project related donations	restricted	98,595	134,000
General donations	restricted	120,875	-
	unrestricted funds	193,464	108,450
Legacies	unrestricted funds	44,156	-
		457,090	242,450

The Trust benefits greatly from the enthusiastic support of its many volunteers, details of which are given in our annual report. In accordance with FRS 102 and the Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the accounts.

2. Investment income

		2018	2017
		£	£
Bank interest receivable	unrestricted funds	5,109	13,816
Investment income	unrestricted funds	9,021	9,178
	restricted	2,762	2,810
		16,892	25,804

3. Cost of generating voluntary fund income

		2018	2017
		£	£
Fundraising Costs	Salaries	38,237	35,198
	Events	37,984	31,248
Support Costs allocated (note 5)		80,827	80,869
		157,048	147,315

Notes to the Financial Statements (continued)

4. Charitable activities

	2018	2017
	£	£
Research grants	424,608	371,204
Research costs	3,757	688
Governance costs (Note 6)	33,908	35,135
	462,273	407,027

All grants are payable to The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research to cover salaries, tuition fees and laboratory consumables.

5. Support costs

	2018	2017
	£	£
Sub-contractors	35,633	29,670
Marketing and PR	6,090	10,634
Printing, postage, stationery and website	17,022	13,422
Other office, travel and sundry	24,552	24,138
Recruitment	-	5,444
Legal and professional fees	-	-
Allocated to Governance costs (Note 5)	(2,470)	(2,439)
	80,827	80,869

The Trust identifies its support costs, it then identifies these costs within this relating to Governance. The remaining support costs are allocated between Costs of Generating Funds and Governance. Staff and related costs are allocated on a time basis, overheads and allocated in proportion to staff time.

6. Governance costs

	2018	2017
	£	£
Bookkeeping and external scrutiny	31,438	26,096
Legal fees relating to investments	-	6,600
Support costs allocated (Note 5)	2,470	2,439
	33,908	35,135

Notes to the Financial Statements (continued)

7. Net expenditure for the year

This is stated after charging (net of VAT):		2018	2017
		£	£
Fees payable to the Auditor:	Audit Services	8,000	8,000
Depreciation charge for the year		393	295
		8,393	8,295

The above figures exclude VAT in accordance with accounting reporting requirements. The actual cost to the charity was £9,400 (2017 : £8,400)

8. Staff costs, Trustee Remuneration and Key Management Personnel

		2018	2017
		£	£
Salaries		36,923	34,414
Social Security costs		968	59
Pension contributions		314	-
		38,205	34,473

During the year the average number of employees was 1 (2017 : 1).

Additional support has been provided throughout the year in administering and running the charity by individuals who are contracted on a self-employed basis, this includes the head of operations.

In both 2017 and 2018 : no employee earned more than £60,000 in that year.

The key management personnel of the Charity comprise the trustees and the head of marketing and operations. The total compensation paid to key management personnel amounted to £21,595 (2017 : £29,636). No trustee was remunerated in the current or preceding year. Total key management personnel consists of one (2017 : one individual).

Notes to the Financial Statements (continued)

9. Tangible fixed assets

	2018
	Computer Equipment £
Cost	
At 31 May 2017	1,180
Additions	-
At 31 May 2018	<u>1,180</u>
Depreciation	£
At 31 May 2017	295
Charge for the year	393
At 31 May 2018	<u>688</u>
Net Book Value	£
At 31 May 2018	<u>492</u>
At 31 May 2017	<u>885</u>

10. Investments

Movement	Investment Funds		Total
	Restricted	Unrestricted	
	£	£	£
Market value at 31st May 2017	84,859	277,194	362,053
Disposal proceeds	(82,679)	(270,072)	(352,751)
Realised losses	(2,180)	(7,122)	(9,302)
Market value at 31 May 2018	-	-	-
Historical cost value at 31 May 2017	<u>75,003</u>	<u>245,001</u>	<u>320,004</u>
Historical cost value at 31 May 2018	-	-	-

All investment holdings were disposed during the year ended 31 May 2018.

Notes to the Financial Statements (continued)

11. Debtors

	2018	2017
	£	£
Grant and event debtors	-	2,012
Other debtors and prepayments	6,688	4,260
Accrued income:		
- Event income	28,991	-
- Gift Aid and bank interest	23,884	16,721
	59,563	22,993

12. Creditors - due within 1 year

	2018	2017
	£	£
Grant accruals	337,219	332,084
Deferred income and other accruals	9,600	9,600
Trade creditors	84,721	91,821
Social security and other taxes	842	855
Other loans	25,001	-
	457,383	434,360

13. Creditors - due after 1 year

	2018	2017
	£	£
Grant accruals - due between 1 and 2 years	8,566	18,086
Other loans - repayable 2-5 years	25,001	73,003
	33,567	93,089

The loan amounts outstanding represent two (2017 : three) separate loans made by individuals under the Oracle Cancer Trust endowment loan arrangement.

The loans are interest free and unsecured. Of the two outstanding loans, one was repaid in June 2018. The lender of the remaining loan has expressed an intention to convert this to a donation. Included in creditors are financial instruments of £490,108 (2017 : £526,592). This balance is made of up short and long-term creditors as per notes 12 and 13 and excludes deferred income and social security taxes.

Notes to the Financial Statements (continued)

14. Restricted Funds

	Balance	Movement in Funds			Gains/(losses)	Balance
	1 June 2017	Income	Expenditure	Transfers		31 May 2018
	£	£	£	£	£	£
Bender Family Trust	20,833	-	-	-	-	20,833
CHK Charities	108,567	-	(32,717)	-	-	75,850
Karsten Schubert Robotic Surgery Fellowship	12,570	100	-	-	-	12,670
Mark Donegan Fellowship	(43,661)	62,500	(48,123)	29,284	-	-
Sarasin Investment Fund	12,666	2,762	-	(4,416)	(2,180)	8,832
The Swire/Adrian Swire Charitable Trust	99,800	-	15,102	-	-	114,902
Swire Robotic Surgery	-	60,000	(50,000)	-	-	10,000
Elise Lopicard PhD	-	37,000	(37,000)	-	-	-
Dr Shree Bhide Project	-	20,000	(20,000)	-	-	-
Julian's Journey	-	39,870	-	-	-	39,870
	210,775	222,232	(172,738)	24,868	(2,180)	282,957

	Balance	Movement in Funds		Transfers	Gains/(losses)	Balance
	1 June 2016	Income	Expenditure			31 May 2017
	£	£	£		£	£
Bender Family Trust	20,833	-	-	-	-	20,833
CHK Charities	141,529	-	(32,962)	-	-	108,567
Karsten Schubert	12,570	-	-	-	-	12,570
Mark Donegan Fellowship	(4,573)	-	(39,088)	-	-	(43,661)
Sarasin Investment Fund	1,768	2,810	-	-	8,088	12,666
Swire Group of Charities	49,800	100,000	(50,000)	-	-	99,800
Hospital Saturday Fund	-	2,000	(2,000)	-	-	-
The Yews Trust	-	2,000	(2,000)	-	-	-
DPS Limited	-	30,000	(30,000)	-	-	-
	221,927	136,810	(156,050)	-	8,088	210,775

Notes to the Financial Statements (continued)

CHK Charities is currently funding PhD student Jennifer Kieselmann who is working at the ICR's Division of Radiotherapy and Imaging. Jennifer is desining software that will allow clinicians to automatically define the boundaries between normal tissues and cancerous tumours on MRI images. Supervised by Prof. Uwe Oelfke, Jennifer's work is supporting the development of the MR-Linac machine which is based at The Royal Marsden Hospital in Sutton. This new machine aims to image and treat patients simulataneously using radiation with precision accuracy, in real-time.

Karsten Schubert will fund projects for **The Karsten Schubert Robotic Surgery Fellowship**.

DPS Limited have pledged funding for five years with year one being a restricted donation to support the salary of Dr Martin McLaughlin's Reovirus project, working under the supervision of Prof. Kevin Harrington.

Hospital Saturday Fund made a restricted donation to support PhD student Elise Lepicard at The Institute of Cancer Research.

Julian's Journey Fundraising is a fund set up by supporter Julian Gilbert who held a year-long series of fundraising events and will be funding PhD student Alexandra Rose's work into the very rare cancer, Adenoid Cystic Carcinoma (ACC).

Sarasin Investment Fund is the movement in the investment value on the restricted part of the Investment portfolio held by investment managers Sarasins. To the extent that the increase in investment values belongs to the Charity it can be drawn upon in accordance with the loan agreement to which the investments are linked.

Sir Samuel Scott of Yews Trust made a restricted donation to support PhD student Elise Lepicard at The Institute of Cancer Research.

The Bender Family Trust funded a three-year post doctoral study for Dr Hind Hafsi at The Institute of Cancer Research to research pre-clinical analyses of a novel anti-cancer agent aimed at enhancing the radiation response in head and neck cancer patients. This study has concluded and there are residual funds which will be re-allocated to fund another clinical project following consultation with the family trust.

The Mark Donegan Fellowship is supporting using viruses in combination with cancer drugs to treat head and neck cancers. The researcher is assessing the effects of combining oncolytic viruses- viruses that preferentially infect and kill cancer cells- with a huge range of novel compounds to test the efficacy of over 80 therapeutic combinations for head and neck cancer patients. The aim is to combine these virus and drug combinations with cutting-edge immunotherapies to put forward an effective course of treatment for patients in the clinic. The Fellowship received a donation in September 2017 of £50,000 plus Gift Aid.

The Swire/Sir Adrian Swire Charitable Trust is funding towards the establishment of a dedicated thyroid cancer research group at the ICR. Thyroid cancers are the most common endocrine tumours and one of the three most prevalent head and neck cancer types in women. The group that has been established is looking to find specific combinations of drugs that will provide a more effective treatment for patients currently exhibiting the treatment-resistant form of the disease.

Any negative fund balances are rectified in the following financial year through the receipt of further income into the relevant fund.

Notes to the Financial Statements (continued)

15. Unrestricted Funds

	Balance	Movements in Funds		Transfers	Gains	Balance
	1 June 2017	Income	Expenditure			31 May 2018
	£	£	£	£	£	£
Designated funds						
Blair Hesketh Memorial Lecture	68,864	-	-	-	-	68,864
General unrestricted funds	659,701	352,928	(446,583)	(24,868)	(7,122)	534,056
	728,565	352,928	(446,583)	(24,868)	(7,122)	602,920

	Balance	Movements in Funds		Transfers	Gains / (losses)	Balance
	1 June 2016	Income	Expenditure			31 May 2017
	£	£	£	£	£	£
Designated funds						
Blair Hesketh Memorial Lecture	69,532	-	668	-	-	68,864
General unrestricted funds	833,641	197,267	(397,624)	-	26,417	659,701
	903,173	197,267	(398,292)	-	26,417	728,565

The Blair Hesketh Memorial Lecture is a fellowship that funds for a leading ENT clinician to deliver the keynote speech at the annual BAHNO (British Association of Head and Neck Oncologists) conference held in London.

16. Trustees' Remuneration and Expenses

No Trustee received any remuneration or reimbursement for expenses in respect of the current year or preceding period.

17. Related Party Transactions

Three Trustee Directors also sit on the Research Sub-Committee. Consequently they make recommendations upon the direction of the research, allocation of funding and related appointments. There is potential for indirect benefit to accrue to these medical Trustee Directors, for example, where the funded appointee delivers a partial clinical role which may alleviate their own clinical responsibilities. To mitigate the risk of related party benefit, the Research Sub-Committee is chaired by an independent Non-Executive Director and it formally passes any funding proposals to the Finance and Investment Sub-Committee (whose members are non-medical) for review and necessary approval before onwards submission for a final Board decision.

One person (2017 : One) is considered key management personnel during the year. The total employee benefits of the key management personnel were £21,595 (2017 : 29,636). This individual is not an employee of Oracle Cancer Trust and works on a consultancy basis.

During the year a trustee converted his loan of £25,001 to an unrestricted donation in the year ended 31 May 2018 in connection with the closure of the loan-based endowment fund.

There were no other transactions in the current or previous period with related parties that required disclosure.

Notes to the Financial Statements (continued)

18. Analysis of Net Assets Between Funds

	Unrestricted	Designated	Restricted	2018 Total
	£	£	£	£
Tangible fixed assets	492	-	-	492
Debtors	47,063	-	12,500	59,563
Cash at bank and in hand	755,816	68,864	492,092	1,316,772
Creditors due within one year	(268,990)	-	(188,393)	(457,383)
Creditors due 1 - 2 years	(325)	-	(8,241)	(8,566)
Creditors due 2 to 5 years	-	-	(25,001)	(25,001)
Balance on Fund	534,056	68,864	282,957	885,877

19. Control

The Charity is controlled by the Trustees under the terms of the Trust Deed.

20. Grants Approved but not Committed

At the year end the charity has agreed to provide research grants over the next 1 - 4 years as follows:

2018/19 - £260,960
 2019/20 - £307,071
 2020/21 - £95,339
 2021/22 - £18,482

These amounts are subject to annual reviews and reporting requirements of the grant recipient. The amounts are funded from reserves and fundraising activities.

These amounts are not provided for in the financial statements as they are subject to annual financial and scientific review.

Notes to the Financial Statements (continued)

21. Operating Leases

At 31st May total commitments under a licence for use of office space:	2018	2017
	£	£
Amounts due less than 1 year - Office equipment	3,412	3,281
	<u>3,412</u>	<u>3,281</u>

This page is intentionally blank



Oracle Cancer Trust
10 Parsons Green House, 27 Parsons Green Lane
London SW6 4HH

Company Registration Number 7125497
Registered Charity Number 1142037

Registered with

